AP828A - Process and crystal forms of 2-methyl-thieno-benzodiazepine. - Google Patents

Process and crystal forms of 2-methyl-thieno-benzodiazepine. Download PDF

Info

Publication number
AP828A
AP828A APAP/P/1997/001065A AP9701065A AP828A AP 828 A AP828 A AP 828A AP 9701065 A AP9701065 A AP 9701065A AP 828 A AP828 A AP 828A
Authority
AP
ARIPO
Prior art keywords
olanzapine
polymorph
active ingredient
methyl
ray powder
Prior art date
Application number
APAP/P/1997/001065A
Other languages
English (en)
Other versions
AP9701065A0 (en
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP828(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of AP9701065A0 publication Critical patent/AP9701065A0/xx
Application granted granted Critical
Publication of AP828A publication Critical patent/AP828A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1997/001065A 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine. AP828A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
AP9701065A0 AP9701065A0 (en) 1997-10-31
AP828A true AP828A (en) 2000-04-28

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001065A AP828A (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine.

Country Status (49)

Country Link
US (1) US5736541A (xx)
EP (3) EP1445259B1 (xx)
JP (1) JPH11502535A (xx)
KR (1) KR100399688B1 (xx)
CN (1) CN1065536C (xx)
AP (1) AP828A (xx)
AR (2) AR010448A1 (xx)
AT (4) AT406771B (xx)
AU (1) AU706471B2 (xx)
BG (1) BG62619B1 (xx)
BR (1) BR9607790A (xx)
CA (1) CA2214005C (xx)
CH (1) CH690579A5 (xx)
CO (1) CO4650278A1 (xx)
CZ (1) CZ292688B6 (xx)
DE (4) DE69614426T2 (xx)
DK (4) DK0733635T3 (xx)
EA (1) EA000149B1 (xx)
EE (1) EE03489B1 (xx)
EG (1) EG23659A (xx)
ES (3) ES2159346T3 (xx)
FI (1) FI973750A0 (xx)
GB (1) GB2313835B (xx)
HK (1) HK1013988A1 (xx)
HU (1) HU224989B1 (xx)
IL (1) IL117610A (xx)
IS (1) IS1896B (xx)
LT (1) LT4349B (xx)
LU (1) LU90096B1 (xx)
LV (1) LV12018B (xx)
MY (1) MY114701A (xx)
NO (1) NO314663B1 (xx)
NZ (1) NZ306110A (xx)
OA (1) OA10510A (xx)
PA (1) PA8353701A1 (xx)
PE (1) PE44897A1 (xx)
PL (1) PL183723B1 (xx)
PT (3) PT1095941E (xx)
RO (1) RO118872B1 (xx)
SE (1) SE9703205D0 (xx)
SI (4) SI1445259T1 (xx)
SK (1) SK284143B6 (xx)
SV (1) SV1996000031A (xx)
TR (1) TR199701017T1 (xx)
TW (2) TW442488B (xx)
UA (1) UA44765C2 (xx)
WO (1) WO1996030375A1 (xx)
YU (1) YU49478B (xx)
ZA (2) ZA962342B (xx)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EP0852496A4 (en) * 1995-09-29 1998-11-11 Lilly Co Eli METHOD FOR TREATING CHRONIC ICT
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
AU721338B2 (en) * 1996-03-25 2000-06-29 Eli Lilly And Company Method for treating pain
BR9708254A (pt) * 1996-03-25 1999-08-03 Lilly Co Eli Método para o tratamento da dor
CA2250186A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
JP2000507546A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 麻酔方法
RS49597B (sr) * 1996-09-23 2007-06-04 Eli Lilly And Company, Olanzapin dihidrat d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
EA002580B1 (ru) * 1998-09-30 2002-06-27 Эли Лилли Энд Компани Готовая препаративная форма 2-метил-тиено-бензодиазепина
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2004507548A (ja) * 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
EP1440074A1 (en) * 2001-10-29 2004-07-28 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
US6906062B2 (en) 2001-12-24 2005-06-14 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (ja) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
EP1513846B1 (en) 2002-05-31 2011-03-02 Sandoz Ag Process of preparation of olanzapine form i
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004108700A1 (en) * 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of polymorphic forms of desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
PL1611139T3 (pl) * 2003-12-22 2008-10-31 Teva Pharma Sposób wytwarzania olenzapiny
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
ATE511512T1 (de) 2005-01-05 2011-06-15 Lilly Co Eli Olanzapinpamoat-dihydrat
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
KR20070113277A (ko) * 2005-03-21 2007-11-28 닥터 레디스 레보러터리즈 리미티드 올란자핀의 결정 형태 ｉ의 제조방법
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
EP3581195A1 (en) 2012-08-21 2019-12-18 Janssen Pharmaceutica NV Antibodies to olanzapine haptens and use thereof
ES2807902T3 (es) 2012-08-21 2021-02-24 Janssen Pharmaceutica Nv Anticuerpos para olanzapina y uso de los mismos
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (en) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
TW268005B (xx) * 1992-05-29 1996-01-11 Lilly Industries Ltd
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
SV1996000031A (es) 1998-03-27
KR19980703188A (ko) 1998-10-15
DE69614426T2 (de) 2002-05-23
GB2313835A (en) 1997-12-10
AU5427996A (en) 1996-10-16
EA000149B1 (ru) 1998-10-29
DE69614426D1 (de) 2001-09-20
YU17796A (sh) 1999-03-04
KR100399688B1 (ko) 2004-02-18
SI9620040A (sl) 1998-06-30
CZ300097A3 (en) 1997-12-17
HUP9802824A2 (hu) 1999-06-28
ATA902196A (de) 2000-01-15
LV12018B (en) 1998-09-20
BR9607790A (pt) 1998-07-07
CZ292688B6 (cs) 2003-11-12
LV12018A (lv) 1998-04-20
DK1095941T3 (da) 2004-02-16
UA44765C2 (uk) 2002-03-15
EE03489B1 (et) 2001-08-15
SK121897A3 (en) 1998-03-04
BG101900A (en) 1999-03-31
AU706471B2 (en) 1999-06-17
HK1013988A1 (en) 1999-09-17
CH690579A5 (de) 2000-10-31
ATE251627T1 (de) 2003-10-15
EE9700232A (et) 1998-04-15
GB9719819D0 (en) 1997-11-19
DE19681286T1 (de) 1998-04-02
LT97148A (en) 1998-01-26
ATE331719T1 (de) 2006-07-15
DK1445259T3 (da) 2006-10-16
IS1896B (is) 2003-10-20
SI9620040B (sl) 2002-02-28
DE69630324T2 (de) 2004-07-29
GB2313835B (en) 1998-09-16
TW442488B (en) 2001-06-23
PL183723B1 (pl) 2002-07-31
MX9707183A (es) 1997-11-29
IS4564A (is) 1997-09-22
HUP9802824A3 (en) 2000-01-28
AT406771B (de) 2000-08-25
RO118872B1 (ro) 2003-12-30
EP1445259B1 (en) 2006-06-28
HU224989B1 (en) 2006-05-29
SI1095941T1 (en) 2003-12-31
FI973750A (fi) 1997-09-22
TW513432B (en) 2002-12-11
DK108997A (da) 1997-11-12
PT1095941E (pt) 2004-02-27
US5736541A (en) 1998-04-07
DE69630324D1 (de) 2003-11-13
AR002719A1 (es) 1998-04-29
IL117610A0 (en) 1996-07-23
IL117610A (en) 2001-08-26
NO974365L (no) 1997-09-22
SE9703205L (sv) 1997-09-05
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
ES2208220T3 (es) 2004-06-16
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
NZ306110A (en) 1998-09-24
CN1065536C (zh) 2001-05-09
ZA962344B (en) 1997-09-22
CA2214005C (en) 2001-07-03
JPH11502535A (ja) 1999-03-02
EP1095941A1 (en) 2001-05-02
EP0733635B1 (en) 2001-08-16
EG23659A (en) 2007-03-26
ATE204280T1 (de) 2001-09-15
ES2159346T3 (es) 2001-10-01
EP1095941B1 (en) 2003-10-08
CN1179160A (zh) 1998-04-15
DK0733635T3 (da) 2001-10-08
PL322501A1 (en) 1998-02-02
CA2214005A1 (en) 1996-10-03
FI973750A0 (fi) 1997-09-22
TR199701017T1 (xx) 1998-01-21
DE69636313T2 (de) 2007-05-31
YU49478B (sh) 2006-05-25
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
SI1445259T1 (sl) 2006-10-31
EP0733635A1 (en) 1996-09-25
PT733635E (pt) 2001-12-28
EA199700262A1 (ru) 1998-02-26
MY114701A (en) 2002-12-31
BG62619B1 (bg) 2000-03-31
SI0733635T1 (en) 2002-06-30
SK284143B6 (sk) 2004-10-05
SE9703205D0 (sv) 1997-09-05
LU90096B1 (fr) 1997-07-22
CO4650278A1 (es) 1998-09-03
NO314663B1 (no) 2003-04-28
OA10510A (en) 2002-04-24
EP1445259A1 (en) 2004-08-11
LT4349B (lt) 1998-05-25
ES2266719T3 (es) 2007-03-01
DE69636313D1 (de) 2006-08-10
PE44897A1 (es) 1997-10-22
ZA962342B (en) 1997-09-22

Similar Documents

Publication Publication Date Title
AP828A (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine.
AU720366B2 (en) Olanzapine dihydrate D
AU719441B2 (en) Intermediates and process for preparing olanzapine
EP0828494A1 (en) Method for treating cognitive dysfunction
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
US6506746B2 (en) Method for treating cognitive dysfunction
NZ325035A (en) Method for treating excessive aggression using olanzapine